Clinical trials: Type 1 or Type 2 Diabetes
Diabetes Mellitus, Type 1, Type 2
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 or type 2 diabetes.
- Trial name
- STRIVE (NCT06865989)
- Testing
- Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Insulet Corporation
Diabetes, Diabetes Mellitus, Type 1
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of Levemir® (insulin detemir) on glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542489
- Testing
- insulin detemir, insulin aspart, human soluble insulin
- Where
- Slovakia
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
- Trial name
- STRIVE 2 (NCT07579702)
- Testing
- Omnipod 5 System, Omnipod 6 System
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Insulet Corporation
Diabetic Foot, Foot Ulcer, Diabetic
Use of Santyl in Diabetic Foot Ulcers
This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers…
- Trial name
- NCT02581488
- Testing
- Santyl, Product containing silver
- Where
- 13 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Smith & Nephew, Inc.
Type 1 Diabetes, Type 2 Diabetes
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes.
- Trial name
- NCT04484779
- Testing
- IIM System, Insulin Lispro and/or Insulin Glargine
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542424
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,889 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus
The purpose of this study is to help answer the following research question(s): To test if taking LY2599506 for 12 weeks controls blood sugar better than taking glyburide for 12 weeks.
- Trial name
- NCT01029795
- Testing
- LY2599506, Glyburide
- Where
- 16 sites in Australia, Austria and 5 more
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus
This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00806858
- Testing
- NovoPen® 4
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetic Nephropathy
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme…
- Trial name
- NCT00754143
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kyntra Bio
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Diabetes, Diabetes Mellitus, Type 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00773279
- Testing
- FlexTouch®, FlexPen®
- Where
- 65 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
Primary: To compare the efficacy and safety of Insulin Glulisine to Insulin Lispro in subjects with type 1 or type 2 diabetes mellitus. To compare the frequency of hypoglycemia of Insulin Glulisine to Insulin Lispro.
- Trial name
- NCT00467376
- Testing
- Insulin Glulisine, Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 485 people
- Sponsor
- Sanofi
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00665093
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,569 people
- Sponsor
- Novo Nordisk A/S
Adult Patients With Type 2 Diabetes
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and…
- Trial name
- NCT06871761
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.